<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712774</url>
  </required_header>
  <id_info>
    <org_study_id>V1 08_2018</org_study_id>
    <nct_id>NCT03712774</nct_id>
  </id_info>
  <brief_title>Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer</brief_title>
  <acronym>ESOCARE</acronym>
  <official_title>Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational study to evaluate the Quality of life based on standardized EORTC
      questionaires as well as toxicities, functional and oncological outcomes in patients treated
      with neoadjuvant or definitive chemoradiation for esophageal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective observational study to evaluate the Quality of life based in patients treated
      with neoadjuvant or definitive chemoradiation for esophageal Cancer. QoL will be evaluated by
      standardized EORTC questionaires. Acute and late toxicity will be assessed according to CTCAE
      4.03. Outcome measures will include local Control, distant Control, freedom from Treatment
      failure and overall survival. Correlations are planned between Patient- and
      physician-assessed functional Outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>planning CT (day 0), week 4 of RT, 6 weeks after end of RT, 3 months after end of RT, 6 months after end of RT, 12 months after end of RT, 24, 36, 48, and 60 months after end of RT</time_frame>
    <description>Quality of life measured by standardized EORTC questionaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>3 months after end of RT, 6 months after end of RT, 9 months after end of RT, 12 months after end of RT, 24,36,48,60 months after end of RT</time_frame>
    <description>Absence of local progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Control</measure>
    <time_frame>3 months after end of RT, 6 months after end of RT, 9 months after end of RT, 12 months after end of RT, 24,36,48,60 months after end of RT</time_frame>
    <description>Absence of distant metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from treatment failure</measure>
    <time_frame>3 months after end of RT, 6 months after end of RT, 9 months after end of RT, 12 months after end of RT, 24,36,48,60 months after end of RT</time_frame>
    <description>Absence of local and distant failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months after end of RT, 6 months after end of RT, 9 months after end of RT, 12 months after end of RT, 24,36,48,60 months after end of RT</time_frame>
    <description>Absence of death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>end of RT, 6 weeks after end of RT, 3 months after end of RT</time_frame>
    <description>acute toxicity scored according to CTCAE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>6 months after end of RT, 9 months after end of RT, 12, 24, 36, 48, 60 months after end of RT</time_frame>
    <description>late toxicity scored according to CTCAE 4.03</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Quality of Life</condition>
  <condition>Chemoradiation</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant chemoradiation</arm_group_label>
    <description>Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>definitive chemoradiation</arm_group_label>
    <description>Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ C30</intervention_name>
    <description>standardized questionaire</description>
    <arm_group_label>definitive chemoradiation</arm_group_label>
    <arm_group_label>neoadjuvant chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ OES-18</intervention_name>
    <description>standardized questionaire</description>
    <arm_group_label>definitive chemoradiation</arm_group_label>
    <arm_group_label>neoadjuvant chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC OG-25</intervention_name>
    <description>standardized questionaire</description>
    <arm_group_label>definitive chemoradiation</arm_group_label>
    <arm_group_label>neoadjuvant chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        see eligibility criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant
             metastases (except supraclavicular nodes)

          -  indication for neoadjuvant or definitive chemoradiation using either cisplatin/5-FU or
             carboplatin/paclitaxel with curative intent

          -  age &gt;= 18 years

          -  written informed consent

          -  ability to answer the standardized questionaires according to the treating physician

        Exclusion Criteria:

          -  age &lt; 18 years

          -  Treatment with palliative intent

          -  distant metastases (except supraclavicular nodes)

          -  second malignancy

          -  Prior systemic treatment for esophageal Cancer

          -  Treatment in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Falk Roeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk Roeder, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73729</phone_ext>
    <email>Falk.Roeder@t-online.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franziska Walter, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73770</phone_ext>
    <email>Franziska.Walter@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University Hospital, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Roeder, MD</last_name>
      <phone>+49 89 4400 73729</phone>
      <email>Falk.Roeder@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Walter, MD</last_name>
      <phone>+49 89 4400 73770</phone>
      <email>Franziska.Walter@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Gerum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Hoffmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Falk Roeder</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>definitive</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

